IL145140A0 - Improved aqueous solubility pharmaceutical formulations - Google Patents

Improved aqueous solubility pharmaceutical formulations

Info

Publication number
IL145140A0
IL145140A0 IL14514000A IL14514000A IL145140A0 IL 145140 A0 IL145140 A0 IL 145140A0 IL 14514000 A IL14514000 A IL 14514000A IL 14514000 A IL14514000 A IL 14514000A IL 145140 A0 IL145140 A0 IL 145140A0
Authority
IL
Israel
Prior art keywords
active agent
stabilized
formulation
composition
pharmaceutical formulations
Prior art date
Application number
IL14514000A
Other languages
English (en)
Original Assignee
Fmc Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fmc Corp filed Critical Fmc Corp
Publication of IL145140A0 publication Critical patent/IL145140A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14514000A 1999-03-24 2000-03-20 Improved aqueous solubility pharmaceutical formulations IL145140A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12591499P 1999-03-24 1999-03-24
US14968099P 1999-08-19 1999-08-19
PCT/US2000/007298 WO2000056726A1 (fr) 1999-03-24 2000-03-20 Formulations pharmaceutiques a solubilite aqueuse amelioree

Publications (1)

Publication Number Publication Date
IL145140A0 true IL145140A0 (en) 2002-06-30

Family

ID=26824087

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14514000A IL145140A0 (en) 1999-03-24 2000-03-20 Improved aqueous solubility pharmaceutical formulations
IL145140A IL145140A (en) 1999-03-24 2001-08-27 A granular particle, a solid dosage form containing it and a method for its preparation

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL145140A IL145140A (en) 1999-03-24 2001-08-27 A granular particle, a solid dosage form containing it and a method for its preparation

Country Status (14)

Country Link
US (3) US6497905B1 (fr)
EP (1) EP1163234B1 (fr)
JP (1) JP2003531099A (fr)
CN (1) CN1156461C (fr)
AT (1) ATE307808T1 (fr)
AU (1) AU3900300A (fr)
BR (1) BR0009176A (fr)
CA (1) CA2362728C (fr)
DE (1) DE60023465T2 (fr)
DK (1) DK1163234T3 (fr)
ES (1) ES2251985T3 (fr)
IL (2) IL145140A0 (fr)
TW (1) TWI245644B (fr)
WO (1) WO2000056726A1 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2381453A (en) * 1999-08-31 2003-05-07 Bradford Particle Design Ltd Active/polymer coformulations
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
IL156310A0 (en) * 2000-12-22 2004-01-04 Baxter Int Method for preparing submicron particle suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6663897B2 (en) 2001-02-06 2003-12-16 Dsm Ip Assets B.V. Oral itraconazole formulations and methods of making the same
US8071133B2 (en) * 2001-08-20 2011-12-06 Stiefel Laboratories, Inc. Oral dosage forms of water insoluble drugs and methods of making the same
BR0306806A (pt) * 2002-01-08 2004-12-07 Can Technologies Inc Ingrediente de alimentação encapsulado
SG165154A1 (en) 2002-02-28 2010-10-28 Japan Tobacco Inc Ester compound and medical use thereof
US8840928B2 (en) * 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US7399488B2 (en) 2002-07-05 2008-07-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8557291B2 (en) 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
DE10247037A1 (de) * 2002-10-09 2004-04-22 Abbott Gmbh & Co. Kg Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers
US20040086567A1 (en) * 2002-10-30 2004-05-06 Pawan Seth Bioequivalent composition of itraconazole and a hydrophilic polymer
EP1603548A4 (fr) * 2003-02-05 2007-10-10 Myriad Genetics Inc Composition et methode de traitement de troubles neurodegeneratifs
WO2005004763A1 (fr) * 2003-07-01 2005-01-20 Pharmacia & Upjohn Company Llc. Formes solides modulees a couche de diffusion
HU227142B1 (en) * 2003-07-02 2010-08-30 Egis Gyogyszergyar Nyilvanosan Capsule of improved release containing fluconazole
CA2532207A1 (fr) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Procedes pharmaceutiques, posologies et formes posologiques pour le traitement de la maladie d'alzheimer
GB0319797D0 (en) * 2003-08-26 2003-09-24 Leuven K U Res & Dev Particle size reduction of poorly soluble drugs
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
EP1669345A4 (fr) 2003-08-29 2008-02-20 Japan Tobacco Inc Derive d'ester et utilisation medicale de celui-ci
US7413690B1 (en) 2003-10-29 2008-08-19 The University Of Mississippi Process and apparatus for producing spherical pellets using molten solid matrices
WO2006001877A2 (fr) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Composition pharmaceutique et methode de traitement de troubles neurodegeneratifs
AU2005241023A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
US7507823B2 (en) 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
DK1765292T3 (en) 2004-06-12 2018-01-02 Collegium Pharmaceutical Inc ABUSE PREVENTIONAL PHARMACEUTICAL FORMULATIONS
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006020852A2 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
WO2006020850A2 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
AU2005297923B2 (en) * 2004-10-25 2010-12-23 Japan Tobacco Inc. Solid medicinal preparation improved in solubility and stability and process for producing the same
US20070042034A1 (en) * 2005-07-22 2007-02-22 Myriad Genetics, Incorporated High drug load formulations and dosage forms
CN100430055C (zh) * 2005-11-11 2008-11-05 天津泰普药品科技发展有限公司 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸和聚乙烯吡咯烷酮玻璃态固溶体及其制备方法
JP2007308479A (ja) 2006-04-20 2007-11-29 Shin Etsu Chem Co Ltd 固体分散体製剤
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
GB0818403D0 (en) * 2008-10-08 2008-11-12 Univ Leuven Kath Aqueous electrophoretic deposition
EP2334845A2 (fr) * 2008-10-06 2011-06-22 Katholieke Universiteit Leuven K.U. Leuven R&D Couches fonctionnelles de biomolécules et de cellules vivantes et nouveau système pour produire celles-ci
MX2011006307A (es) 2008-12-15 2011-10-14 Banner Pharmacaps Inc Metodos para aumentar la liberacion y absorcion de agentes activos insolubles en agua.
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US20110150993A1 (en) * 2009-12-22 2011-06-23 Fmc Corporation Fine Particle Croscarmellose and Uses Thereof
EP2601973A1 (fr) * 2011-12-09 2013-06-12 Laboratoires SMB SA Formulation de poudre sèche de dérivé d'azole pour inhalation
JP2014122328A (ja) * 2012-11-22 2014-07-03 Shin Etsu Chem Co Ltd 押出成形機又は射出成形機洗浄用組成物及び押出成形機又は射出成形機の洗浄方法
GB201602579D0 (en) * 2016-02-12 2016-03-30 Mihranyan Albert New compositions
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
JP7378393B2 (ja) * 2017-11-10 2023-11-13 オースティンピーエックス リミテッド ライアビリティ カンパニー 改善された薬物製剤

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2907460A1 (de) * 1978-03-07 1979-09-13 Sandoz Ag Neue resorbierbare galenische kompositionen
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
GB8506792D0 (en) 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US5118799A (en) 1987-05-12 1992-06-02 Pharmacin Corporation Process for converting crystalline erythromycin ethylsuccinate into stable amorphous erythromycin ethylsuccinate
EP0462066A1 (fr) 1990-06-15 1991-12-18 Warner-Lambert Company Gemfibrozil amorphe
JP2829794B2 (ja) * 1991-02-08 1998-12-02 エスエス製薬 株式会社 徐放性経口投与型プラノプロフェン製剤
US5208015A (en) 1991-07-23 1993-05-04 Bristol-Myers Squibb Company Topical anti-fungal agents having anti-inflammatory activity
US5200195A (en) * 1991-12-06 1993-04-06 Alza Corporation Process for improving dosage form delivery kinetics
ATE138561T1 (de) 1992-02-12 1996-06-15 Janssen Cilag S P A Liposomale itraconazol formulierungen
NZ249494A (en) 1992-03-18 1996-04-26 Janssen Pharmaceutica Nv Itraconazole and saperconazole stereoisomers; pharmaceutical compositions
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
IT1256386B (it) * 1992-11-13 1995-12-04 Luigi Boltri Composizioni farmaceutiche comprendenti un farmaco,una sostanza polimerica reticolata,un olio ed un agente tensioattivo
TW349870B (en) 1993-09-30 1999-01-11 Janssen Pharmaceutica Nv An antifungal pharmaceutical composition for oral administration and a process for the preparation thereof
US5565478A (en) 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
FR2722984B1 (fr) 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
US5976555A (en) 1994-09-07 1999-11-02 Johnson & Johnson Consumer Products, Inc. Topical oil-in-water emulsions containing retinoids
TW487582B (en) 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
EP0862463A1 (fr) 1995-11-23 1998-09-09 Janssen Pharmaceutica N.V. Melanges solides de cyclodextrines prepares par fusion-extrusion
US5646151A (en) * 1996-03-08 1997-07-08 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
KR19990044257A (ko) * 1996-05-20 1999-06-25 디르크 반테 생체이용율이 개선된 항진균성 조성물
US5972381A (en) * 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
US6517860B1 (en) * 1996-12-31 2003-02-11 Quadrant Holdings Cambridge, Ltd. Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery
SI0969821T1 (en) 1997-03-26 2003-10-31 Janssen Pharmaceutica N.V. Pellets having a core coated with an antifungal and a polymer
US5813416A (en) 1997-04-03 1998-09-29 Rudolph; James M. File with sanitizing agent
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
KR19990001564A (ko) 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제

Also Published As

Publication number Publication date
DE60023465D1 (de) 2005-12-01
ES2251985T3 (es) 2006-05-16
CN1379768A (zh) 2002-11-13
US6497905B1 (en) 2002-12-24
US6379707B2 (en) 2002-04-30
CA2362728C (fr) 2009-06-23
JP2003531099A (ja) 2003-10-21
WO2000056726A1 (fr) 2000-09-28
BR0009176A (pt) 2001-12-18
CA2362728A1 (fr) 2000-09-28
DE60023465T2 (de) 2006-07-20
IL145140A (en) 2006-08-20
EP1163234B1 (fr) 2005-10-26
CN1156461C (zh) 2004-07-07
AU3900300A (en) 2000-10-09
US6511681B2 (en) 2003-01-28
DK1163234T3 (da) 2006-02-27
US20020012706A1 (en) 2002-01-31
TWI245644B (en) 2005-12-21
US20020037324A1 (en) 2002-03-28
EP1163234A1 (fr) 2001-12-19
ATE307808T1 (de) 2005-11-15
EP1163234A4 (fr) 2003-05-02

Similar Documents

Publication Publication Date Title
IL145140A0 (en) Improved aqueous solubility pharmaceutical formulations
DE60038097D1 (de) Feste orale dosierungsform enthaltend einen resorptionsverstärker
CA2370565A1 (fr) Compositions pharmaceutiques contenant de la vitamine d pour application cutanee
CA2328950A1 (fr) Derives de piperidinopyrimidine pour application topique
WO2001032596A8 (fr) Composes d'acide carboxylique phenoxy et compositions utilisees afin de diffuser des agents actifs
CA2382098A1 (fr) Formes de presentation pharmaceutiques orales a action retardee
WO2001095856A3 (fr) Derive d'uree en tant qu'agent anticancereux et son procede de preparation
WO2002019969A3 (fr) Acide (5-(2-hydroxy-4-chlorobenzoyl) aminovalerique et ses sels, compositions contenant l'acide et ses sels pour acheminer des agents actifs
WO2000045800A3 (fr) Effets immunosuppresseurs des derives de pteridine
EA200000154A1 (ru) Способ солюбилизации фармацевтически активных ингредиентов в воде и в водных носителях
EP1057484A4 (fr) Inhibiteurs de la mort cellulaire
JP2000159790A5 (fr)
CA2304135A1 (fr) Formulation medicamenteuse a liberation controlee du principe actif
CA2352915A1 (fr) Compositions pharmaceutiques renfermant de la mupirocine
PL350419A1 (en) Directly compressible matrix for controlled release of single daily doses of clarithromycin
MXPA02001804A (es) Composicion para inhalacion que comprende delta-9-tetrahidrocanabinol en un solvente semi-acuoso.
AU3669700A (en) 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient
CA2380757A1 (fr) Agent pharmaceutique comprenant un derive benzamide comme principe actif
WO2002009717A1 (fr) Remedes contre la dyserection contenant des derives de prostaglandine comme principe actif
WO2004069187A3 (fr) Formulation et administration d'un medicament a l'aide de cyclodextrines cristallines methylees
EP1219296A4 (fr) Inhibiteurs de la production de sebum
CA2397942A1 (fr) Composition pharmaceutique a liberation regulee contenant du chlorhydrate de tramadol et son procede de preparation
WO2002011709A3 (fr) Formulation pharmaceutique effervescente contenant du ramipril
WO2001017955A3 (fr) Composes chimiques
EP1149832A4 (fr) Derives de benzamide et medicaments les contenant

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed